All In Biotech

Drug Trial Radar · NCT06381180

Warrior CARE: Cannabis Behavioral Health

Wayne Warrior CAnnabis Research and Education: Cannabis and Behavioral Health

Last checked: Nov 20, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 500 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

500

Planned (sponsor's estimate)

Start

Sep 22, 2025

Primary completion

Dec 31, 2030

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Wayne State UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Apr 24, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 19 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, controlled clinical trial to examine the therapeutic potential of cannabinoids for treating veterans with PTSD and suicidal ideation.

Conditions

  • Post Traumatic Stress Disorder
  • Cannabis Use
  • Suicide
  • Veterans
  • Marijuana

Interventions

  • TetrahydrocannabinolDrug

    Plant cannabis that will be smoked

  • CannabidiolDrug

    Plant cannabidiol that will be smoked

  • PlaceboDrug

    Plant will be smoked.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessing change in PTSD diagnosis and its symptom severity from pre-treatment to post-treatment using the CAPS-5 assessment.Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).
  2. Assessing change in PTSD diagnosis and its symptom severity throughout the study using the PCL-5 assessmentTime frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months
  3. Assessing Suicidality over time using the C-SSRS assessment.Time frame: Administered at a pre-treatment visit (at the initial screening visit); and at the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months post-treatment visits).
  4. Assessing Suicidality throughout the study using the SBQ-R assessment.Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months
  5. Assessing mood and anxiety symptoms throughout the study using the BDI-II and STAI-Y Questionnaires.Time frame: Administered at every study visit: both pre-treatment visits (the initial screening and baseline visit); during the 12-week treatment phase (all twelve weekly visits); and the four post-treatment visits (one week post-treatment and 3-, 6-, and 9-months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Wayne State University

    Detroit, Michigan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.